Cost-effectiveness analysis of bicalutamide (Casodex™) for adjuvant treatment of early prostate cancer

Value in Health

Volumn 7, Issue 4, 2004, Pages 472-481

  Moeremans, Karen ^a   Caekelbergh, Karin ^a   Annemans, Lieven ^a,b,c  

^a Health Economics and Disease Management   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c HEDM   (Belgium)

Author keywords

Adjuvant; Bicalutamide; Cost effectiveness; Early prostatic neoplasm

Indexed keywords

BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; FLUTAMIDE; GOSERELIN; TAMOXIFEN;

ADULT; ARTICLE; BELGIUM; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; EARLY CANCER; FOLLOW UP; GYNECOMASTIA; HEALTH CARE COST; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MEDICAL RECORD; METASTASIS; OUTCOMES RESEARCH; PATIENT CARE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE CANCER; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SENSITIVITY ANALYSIS; STATISTICAL MODEL; VALIDATION PROCESS;

EID: 3843055594     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2004.74010.x     Document Type: Article

References (26)

1. Kolvenbag GJ, Iversen P, Newling DW. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology 2001;58 (Suppl. 1):16-23.
2. Grossfeld GD, Stier DM, Flanders SC, et al. Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database. J Urol 1998;160:1398-404.
3. See WA, Wirth MP, McLeod DG, et al. on behalf of the Casodex early prostate cancer Trialist Group. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168:429-35.
4. Brasso K, Friis S, Juel K et al. Mortality of patients with clinically localised cancer treated with observation for 10 years or longer: a population based registry study. J Urol 1999;161:524-8.
5. Canto EI, Slawin KM. Early management of prostate cancer: how to respond to elevated PSA? Annu Tev Med 2002;53:355-68.
6. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press, 1996.
7. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
8. Briggs A, Sculpher M. An introduction to Markov Modelling for economic evaluation. Pharmacoeconomics 1998;13:397-409.
9. Dicker AP. The safety and tolerability of low dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol 2003;4:30-6.
10. Tyrrell CJ. Gynaecomastia: etiology and treatment options. Prostate Cancer Prostatic Dis 1999;2:167-71.
11. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
12. Witjes JA. Richtlijnen voor controle bij patiënten met prostaatcarcinoom. Ned Tijdschr Geneeskd 2002;146:360-2.
13. Roberts SG, Blute ML, Bergstrahl EJ, et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-81.
14. The Royal College of Radiologists' Clinical Oncology Information Network British Association of Urologie Surgeons. Guidelines on the management of prostate cancer. (COIN/BAUS Guidelines) BJU Int 1999;84:987-1014.
15. Sternberg CN. Systemic treatment and new developments in advanced prostate cancer. Eur J Caner 2001;37(Suppl. 7):S147-57.
16. Smith DS, Krygiel J, Nease RF Jr, et al. Patient preferences for outcomes associated with surgical management or prostate cancer. J Urol 2002;167:2117-22.
17. Saigal CS, Gornbein J, Nease R, et al. Predictors of utilities for health states in early stage prostate cancer. J Urol 2001;166:942-6.
18. Rosendahl I, Kiebert G, Curran D et al. Quality adjusted survival (Q-TWIST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orciectomy in patients with metastatic prostate cancer. Prostate 1999;38:100-9.
19. Bennett CL, Matchar D, McCrory D, et al. Cost-effective models for flutamide for prostate carcinoma patients. Cancer 1998;77:1854-61.
20. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health related quality of life after contemporary therapies for localised prostate cancer. J Clin Oncol 2002;20:557-66.
21. Clark DE. Computational methods for probabilistic decision trees. Computers Biomed Res 1997;30:19-33.
22. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-17.
23. de Vere White R. Present and future management of prostate cancer. Cancer Biother Radiopharm 2000;15:121-5.
24. Neymark N, Adriaenssens I, Gorlia T, et al. Cost-effectiveness of the addition of early hormone therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur J Cancer 2001;37:1768-74.
25. Paltiel AD. Model-based drug evaluationin chronic disease: promise, pitfalls and positioning. Drug Inf J 2001;35:131-9.
26. Harris KA, Reese DM. Treatment options in hormone refractory prostate cancer. Current and future approaches. Drugs 2001;61:2177-92.